Legend Biotech Future Growth
Future criteria checks 5/6
Legend Biotech is forecast to grow earnings and revenue by 63.6% and 35.1% per annum respectively. EPS is expected to grow by 48.7% per annum. Return on equity is forecast to be 19.1% in 3 years.
Key information
63.6%
Earnings growth rate
48.7%
EPS growth rate
Biotechs earnings growth | 28.3% |
Revenue growth rate | 35.1% |
Future return on equity | 19.1% |
Analyst coverage | Good |
Last updated | 10 Oct 2024 |
Recent future growth updates
Recent updates
Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion
Sep 18Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking
Aug 01Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges
Jul 30Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt
Jul 05Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances
May 14Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio
May 13Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)
Mar 15Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?
Mar 06Legend Biotech: Solid Traction With Carvykti Rollout
Jan 29Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up
Jan 16Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?
Nov 09Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?
Apr 12An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued
Dec 14Legend Biotech wins approval of Carvykti for multiple myeloma in Japan
Sep 27Legend Biotech stock slides on proposed ADS offering
Jul 25Legend Biotech ends Phase 1 trial for lymphoma candidate
Jul 07News Flash: Analysts Just Made A Notable Upgrade To Their Legend Biotech Corporation (NASDAQ:LEGN) Forecasts
Jun 05Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?
May 14Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results
Mar 22Legend Biotech: Carvykti Approval Makes For A Buy Opportunity
Mar 04Legend Biotech Corporation (NASDAQ:LEGN) Analysts Are More Bearish Than They Used To Be
Mar 03Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?
Dec 30Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,576 | 137 | 189 | 207 | 15 |
12/31/2025 | 1,020 | -166 | -168 | -174 | 19 |
12/31/2024 | 588 | -273 | -437 | -137 | 18 |
6/30/2024 | 456 | -285 | -165 | -143 | N/A |
3/31/2024 | 343 | -466 | -264 | -239 | N/A |
12/31/2023 | 285 | -518 | -416 | -393 | N/A |
9/30/2023 | 233 | -509 | -371 | -347 | N/A |
6/30/2023 | 165 | -532 | -378 | -359 | N/A |
3/31/2023 | 112 | -517 | -276 | -262 | N/A |
12/31/2022 | 117 | -446 | -224 | -201 | N/A |
9/30/2022 | 106 | -416 | -237 | -221 | N/A |
6/30/2022 | 96 | -457 | -221 | -194 | N/A |
3/31/2022 | 119 | -346 | -293 | -250 | N/A |
12/31/2021 | 69 | -404 | -244 | -198 | N/A |
9/30/2021 | 93 | -356 | -245 | -185 | N/A |
6/30/2021 | 89 | -297 | -259 | -205 | N/A |
3/31/2021 | 80 | -340 | -256 | -204 | N/A |
12/31/2020 | 75 | -266 | -253 | -223 | N/A |
9/30/2020 | 59 | -310 | -300 | -227 | N/A |
6/30/2020 | 64 | -271 | -209 | -143 | N/A |
3/31/2020 | 61 | -165 | -160 | -125 | N/A |
1/1/2020 | 62 | -102 | -110 | -83 | N/A |
12/31/2018 | 49 | -3 | 287 | 308 | N/A |
12/31/2017 | 24 | 9 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LEGN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Earnings vs Market: LEGN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: LEGN is expected to become profitable in the next 3 years.
Revenue vs Market: LEGN's revenue (35.1% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: LEGN's revenue (35.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LEGN's Return on Equity is forecast to be low in 3 years time (19.1%).